Aptose Biosciences Inc. (TSE:APS – Get Free Report) (NASDAQ:APTO) shares hit a new 52-week low during trading on Monday . The company traded as low as C$1.85 and last traded at C$1.84, with a volume of 13836 shares. The stock had previously closed at C$1.90.
Aptose Biosciences Stock Down 0.6 %
The company has a quick ratio of 5.41, a current ratio of 0.78 and a debt-to-equity ratio of 14.27. The business has a 50-day simple moving average of C$2.24 and a two-hundred day simple moving average of C$2.95. The stock has a market capitalization of C$27.34 million, a P/E ratio of -0.17 and a beta of 1.44.
Aptose Biosciences (TSE:APS – Get Free Report) (NASDAQ:APTO) last posted its quarterly earnings data on Tuesday, March 26th. The biotechnology company reported C($1.96) EPS for the quarter, topping analysts’ consensus estimates of C($1.98) by C$0.02. Equities research analysts forecast that Aptose Biosciences Inc. will post -0.59 earnings per share for the current fiscal year.
About Aptose Biosciences
Aptose Biosciences Inc, a clinical-stage biotechnology company, discovers and develops personalized therapies addressing unmet medical needs in oncology in Canada. Its lead clinical program is APTO-253, which is a Phase I clinical trial for the treatment of patients with relapsed or refractory hematologic malignancies.
Recommended Stories
- Five stocks we like better than Aptose Biosciences
- Most active stocks: Dollar volume vs share volume
- United Airlines Soars on Earnings Beat
- Natural Gas Prices Continue To Rally, These Stocks Should Benefit
- J.B. Hunt Hits the Skids: Lower Prices to Come
- Utilities Stocks Explained – How and Why to Invest in Utilities
- Predicting a Bear Market: 7 Signs and Why it’s Tough to Do
Receive News & Ratings for Aptose Biosciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Aptose Biosciences and related companies with MarketBeat.com's FREE daily email newsletter.
